QCZ484 vs Tonlamarsen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensinogen (AGT) · full Hypertension pipeline
QCZ484
Developed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2031 · NCT07543120 (registry estimate)
No aligned efficacy figure on record for this race.
Tonlamarsen
Developed by Kardigan under a licence from Ionis Pharmaceuticals
NCT06864104 · Phase 2 · completed
The study randomized 198 participants (206 entered the active run-in) to monthly tonlamarsen or to a single tonlamarsen dose followed by placebo, with participants, care providers, investigators and outcome assessors masked. It had two co-primary outcomes at week 20. Plasma angiotensinogen fell more with monthly dosing (P<0.0001), but office systolic blood pressure fell by 6.7 mm Hg in both groups (P=0.97). One co-primary outcome was met and one was missed, so the result is mixed. The figures are from the peer-reviewed publication (JACC 2026) and the registry's primary outcome list.
Next expected readout: December 2026 · NCT07511361 (registry estimate)
Reported efficacy
Co-primary: change from baseline to week 20 in plasma angiotensinogen and in office systolic blood pressure (between-group differences): Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. (mixed)
Result source: NCT06864104
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | QCZ484 | Tonlamarsen |
|---|---|---|
| Seated SBP, change | —Not reported | —Not reported |
| 24-hour ambulatory SBP, change | —Not reported | —Not reported |
| Seated DBP, change | —Not reported | —Not reported |
Seated SBP, change
- QCZ484
- —Not reported
- Tonlamarsen
- —Not reported
24-hour ambulatory SBP, change
- QCZ484
- —Not reported
- Tonlamarsen
- —Not reported
Seated DBP, change
- QCZ484
- —Not reported
- Tonlamarsen
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QCZ484: no structured comparison results are available for Hypertension.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: QCZ484's landscape · Tonlamarsen's landscape